The latest price target for GSK (NYSE:GSK) was reported by Jefferies on November 12, 2024. The analyst firm set a price target for $0.00 expecting GSK to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for GSK (NYSE:GSK) was provided by Jefferies, and GSK downgraded their hold rating.

The last upgrade for GSK PLC happened on March 4, 2024 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for GSK PLC.

The last downgrade for GSK PLC happened on November 12, 2024 when Jefferies changed their price target from N/A to N/A for GSK PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GSK, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GSK was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.

While ratings are subjective and will change, the latest GSK (GSK) rating was a downgraded with a price target of $0.00 to $0.00. The current price GSK (GSK) is trading at is $33.74, which is out of the analyst’s predicted range.